: Currently, only one medication (risperidone) is FDA-approved for the treatment of autism spectrum disorders (ASD). Perhaps for this reason, the use of novel, unconventional, and off-label treatments for ASD is common, with up to 74% of children with ASD using these treatments; however, treating physicians are often unaware of this usage.
Methods
A systematic literature search of electronic scientific databases was performed to identify studies of novel and emerging treatments for ASD, including nutritional supplements, diets, medications, and nonbiological treatments. A grade of recommendation (“Grade”) was then assigned to each treatment using a validated evidence-based guideline as outlined in this review:
Supported by at least 2 prospective randomized controlled trials (RCTs) or 1 systematic review
Supported by at least 1 prospective RCT or 2 nonrandomized controlled trials
Supported by at least 1 nonrandomized controlled trial or 2 case series
Troublingly inconsistent or inconclusive studies or studies reporting no improvements
Potential adverse effects for each treatment were also reviewed.
Results
Grade A treatments for ASD include melatonin, acetylcholinesterase inhibitors, naltrexone, and music therapy. Grade B treatments include carnitine, tetrahydrobiopterin, vitamin C, alpha-2 adrenergic agonists, hyperbaric oxygen treatment, immunomodulation and anti-inflammatory treatments, oxytocin, and vision therapy. Grade C treatments for ASD include carnosine, multivitamin/mineral complex, piracetam, polyunsaturated fatty acids, vitamin B6/magnesium, elimination diets, chelation, cyproheptadine, famotidine, glutamate antagonists, acupuncture, auditory integration training, massage, and neurofeedback.
Conclusions
The reviewed treatments for ASD are commonly used, and some are supported by prospective RCTs. Promising treatments include melatonin, antioxidants, acetylcholinesterase inhibitors, naltrexone, and music therapy. All of the reviewed treatments are currently considered off-label for ASD (ie, not FDA-approved) and some have adverse effects. Further studies exploring these treatments are needed. Physicians treating children with an ASD should make it standard practice to inquire about each child's possible use of these types of treatments.
Diagnostic and statistical manual of mental disorders, 4th ed.Washington, DC: American Psychiatric Association;1994.
2.
BairdG, CharmanT, Baron-CohenS, . A screening instrument for autism at 18 months of age: a 6-year follow-up study. J Am Acad Child Adolesc Psychiatry. 2000;39:694–702.
3.
BertrandJ, MarsA, BoyleC, . Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. Pediatrics. 2001;108:1155–1161.
4.
ChakrabartiS, FombonneE.Pervasive developmental disorders in preschool children. JAMA. 2001;285:3093–3099.
5.
RiceC.Prevalence of autism spectrum disorders— autism and developmental disabilities monitoring network, 14 sites, United States, 2002. MMWR. 2007;56:12–28.
6.
MuhleR, TrentacosteSV, RapinI.The genetics of autism. Pediatrics. 2004;113: e472–e486.
7.
GreenVA, PituchKA, ItchonJ, . Internet survey of treatments used by parents of children with autism. Res Dev Disabil. 2006;27:70–84.
8.
AmanMG, LamKS, Collier-CrespinA.Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J Autism Dev Disord. 2003;33:527–534.
9.
WitwerA, LecavalierL.Treatment incidence and patterns in children and adolescents with autism spectrum disorders. J Child Adolesc Psychopharmacol. 2005;15:671–681.
10.
Langworthy-LamKS, AmanMG, Van BourgondienME.Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. J Child Adolesc Psychopharmacol. 2002;12:311–321.
11.
US Food and Drug Administration.FDA approves the first drug to treat irritability associated with autism, risperdal 2006. Available at: http://www.fda.gov/bbs/ topics/news/2006/new01485.html. Accessed May 6, 2009.
12.
ScottLJ, DhillonS.Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs. 2007;9:343–354.
13.
RosebushPI, MazurekMF.Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology. 1999;52:782–785.
14.
HymanSL, LevySE.Introduction: novel therapies in developmental disabilities—hope, reason, and evidence. Ment Retard Dev Disabil Res Rev. 2005;11:107–109.
15.
American Academy of Pediatrics. Counseling families who choose complementary and alternative medicine for their child with chronic illness or disability. Committee on Children With Disabilities. Pediatrics.2001;107:598–601.
16.
PhillipsB, BallC, SackettD, . Oxford Centre for Evidence-based Medicine Levels of Evidence. 2001. Available at: http://www.cebm.net/levels_of_evidence. asp. Accessed May 6, 2009.
17.
SandlerAD, BodfishJW.Placebo effects in autism: lessons from secretin. J Dev Behav Pediatr. 2000;21:347–350.
18.
KingBH, WrightDM, HandenBL, . Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40:658–665.
19.
Defining and describing complementary and alternative medicine. Panel on Definition and Description CAM Research Methodology Conference, April 1995. Altern Ther Health Med.1997;3:49–57.
20.
LomanDG.The use of complementary and alternative health care practices among children. J Pediatr Health Care. 2003;17:58–63.
21.
SandersH, DavisMF, DuncanB, . Use of complementary and alternative medical therapies among children with special health care needs in southern Arizona. Pediatrics. 2003;111:584–587.
22.
WongHH, SmithRG.Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. J Autism Dev Disord. 2006;36:901–909.
23.
HansonE, KalishLA, BunceE, . Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. J Autism Dev Disord. 2007;37:628–636.
24.
WongVC.Use of complementary and alternative medicine (CAM) in autism spectrum disorder (ASD): comparison of Chinese and Western culture (part A). J Autism Dev Disord. 2009;39:454–463.
25.
Autism Research Institute. Parent ratings of behavorial effects of biomedical interventions. ARI Publ 34; February 2008. http://www.autism.com/treatable/ form34qr.htm. Accessed May 6, 2009.
26.
LevySE, MandellDS, MerharS, . Use of complementary and alternative medicine among children recently diagnosed with autistic spectrum disorder. J Dev Behav Pediatr. 2003;24:418–423.
27.
GolnikAE, IrelandM.Complementary alternative medicine for children with autism: a physician survey. J Autism Dev Disord. 2009;39:996–1005.
28.
LiptakGS, OrlandoM, YinglingJT, . Satisfaction with primary health care received by families of children with developmental disabilities. J Pediatr Health Care. 2006;20:245–252.
29.
KemperKJ, O'ConnorKG.Pediatricians’ recommendations for complementary and alternative medical (CAM) therapies. Ambul Pediatr. 2004;4:482–487.
30.
MyersSM, JohnsonCP.Management of children with autism spectrum disorders. Pediatrics. 2007;120:1162–1182.
31.
MuskietFA, KempermanRF.Folate and long-chain polyunsaturated fatty acids in psychiatric disease. Nutr J. Biochem.2006;17:717–727.
LakhanSE, VieiraKF.Nutritional therapies for mental health disorders. Nutr J.2008;7:2.
34.
CarltonRM, EnteG, BlumL, . Rational dosages of nutrients have a prolonged effect on learning disabilities. Altern Ther Health Med. 2000;6:85–91.
35.
BentonD, RobertsG.Effect of vitamin and mineral supplementation on intelligence of a sample of schoolchildren. Lancet. 1988;1:140–143.
36.
OsendarpSJ, BaghurstKI, BryanJ, . Effect of a 12-mo micronutrient intervention on learning and memory in well-nourished and marginally nourished school-aged children: 2 parallel, randomized, placebo-controlled studies in Australia and Indonesia. Am J Clin Nutr. 2007;86:1082–1093.
37.
HaskellCF, ScholeyAB, JacksonPA, . Cognitive and mood effects in healthy children during 12 weeks’ supplementation with multi-vitamin/minerals. Br Nutr J.2008;100:1086–1096.
38.
MacLellanD, TaylorJ, WoodK.Food intake and academic performance among adolescents. Can Diet J. Pract Res.2008;69:141–144.
39.
SchreckKA, WilliamsK, SmithAF.A comparison of eating behaviors between children with and without autism. J Autism Dev Disord. 2004;34:433–438.
40.
HerndonAC, DiGuiseppiC, JohnsonSL, . Does nutritional intake differ between children with autism spectrum disorders and children with typical development?J Autism Dev Disord.2009;39:212–222.
41.
NgF, BerkM, DeanO, . Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int Neuropsychopharmacol J.2008;11:851–876.
42.
TsaluchiduS, CocchiM, TonelloL, . Fatty acids and oxidative stress in psychiatric disorders. BMC Psychiatry. 2008;8:(suppl 1)S5.
43.
YorbikO, SayalA, AkayC, . Investigation of antioxidant enzymes in children with autistic disorder. Prostaglandins Leukot Essent Fatty Acids. 2002;67:341–343.
44.
JamesSJ, MelnykS, JerniganS, . Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet.2006;141:947–956.
45.
JamesSJ, CutlerP, MelnykS, . Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004;80:1611–1617.
46.
ChauhanA, ChauhanV, BrownWT, . Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin— the antioxidant proteins. Life Sci. 2004;75:2539–2549.
47.
ChauhanA, ChauhanV.Oxidative stress in autism. Pathophysiology. 2006;13:171–181.
48.
Sperner-UnterwegerB.Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications. Drugs. 2005;65:1493–1520.
49.
PardoCA, VargasDL, Zimmerman Immunity AW., neuroglia and neuroinflammation in autism. Int Rev Psychiatry.2005;17:485–495.
50.
VargasDL, NascimbeneC, KrishnanC, . Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57:67–81.
51.
ChezMG, DowlingT, PatelPB, . Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol. 2007;36:361–365.
52.
ConnollyAM, ChezMG, PestronkA, . Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. J Pediatr. 1999;134:607–613.
53.
ConnollyAM, ChezM, StreifEM, . Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. Biol Psychiatry. 2006;59:354–363.
54.
TorrenteF, AshwoodP, DayR, . Small intestinal enteropathy with epithelial Ig G and complement deposition in children with regressive autism. Mol Psychiatry. 2002;7:375–382., 334.
55.
FurlanoRI, AnthonyA, DayR, . Colonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism. J Pediatr. 2001;138:366–372.
56.
AshwoodP, AnthonyA, PellicerAA, . Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology. J Clin Immunol. 2003;23:504–517.
57.
BalzolaF, DanielaC, RepiciA, . Autistic enterocolitis: confirmation of a new inflammatory bowel disease in an Italian cohort of patients. Gastroenterology.2005;128:A303.
58.
HorvathK, PapadimitriouJC, RabsztynA, . Gastrointestinal abnormalities in children with autistic disorder. J Pediatr. 1999;135:559–563.
59.
Valicenti-McDermottM, McVicarK, RapinI, . Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. J Dev Behav Pediatr.2006;27:S128–S136.
60.
HorvathK, PermanJA.Autism and gastrointestinal symptoms. Curr Gastroenterol Rep. 2002;4:251–258.
SongY, LiuC, FinegoldSM.Real-time PCR quantitation of clostridia in feces of autistic children. Appl Environ Microbiol. 2004;70:6459–6465.
63.
ParrachoHM, BinghamMO, GibsonGR, . Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J Med Microbiol. 2005;54:987–991.
64.
JyonouchiH, GengL, RubyA, . Evaluation of an association between gastrointestinal symptoms and cytokine production against common dietary proteins in children with autism spectrum disorders. J Pediatr. 2005;146:605–610.
65.
BuieTM.Gastroesophageal reflux in children with autism: how do children present and can one test these children?J Pediatr Gastroenterol Nutr.2005;41:505.
66.
LevySE, HymanSL.Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev. 2005;11:131–142.
67.
NirI, MeirD, ZilberN, . Brief report: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord. 1995;25:641–654.
68.
KulmanG, LissoniP, RovelliF, . Evidence of pineal endocrine hypofunction in autistic children. Neuro Endocrinol Lett. 2000;21:31–34.
69.
TordjmanS, AndersonGM, PichardN, . Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder. Biol Psychiatry. 2005;57:134–138.
JanJE, O'DonnellME.Use of melatonin in the treatment of paediatric sleep disorders. Pineal J. Res.1996;21:193–199.
72.
HayashiE.Effect of melatonin on sleep-wake rhythm: the sleep diary of an autistic male. Psychiatry Clin Neurosci. 2000;54:383–384.
73.
IshizakiA, SugamaM, TakeuchiN.[Usefulness of melatonin for developmental sleep and emotional/behavior disorders—studies of melatonin trial on 50 patients with developmental disorders] [In Japanese]. No To Hattatsu. 1999;31:428–437.
74.
PaavonenEJ, Nieminen-von WendtT, VanhalaR, . Effectiveness of melatonin in the treatment of sleep disturbances in children with Asperger disorder. J Child Adolesc Psychopharmacol. 2003;13:83–95.
75.
GiannottiF, CortesiF, CerquigliniA, . An openlabel study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord. 2006;36:741–752.
76.
AndersenIM, KaczmarskaJ, McGrewSG, . Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol. 2008;23:482–485.
77.
WasdellMB, JanJE, BombenMM, . A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. Pineal J. Res.2008;44:57–64.
78.
GarstangJ, WallisM.Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev. 2006;32:585–589.
79.
WirojananJ, JacquemontS, DiazR, . The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009;5:145–150.
80.
FilipekPA, JuranekJ, NguyenMT, . Relative carnitine deficiency in autism. J Autism Dev Disord. 2004;34:615–623.
81.
EllawayCJ, PeatJ, WilliamsK, . Medium-term open label trial of L-carnitine in Rett syndrome. Brain Dev.2001;23 suppl 1:S85–S89.
82.
EllawayC, WilliamsK, LeonardH, . Rett syndrome: randomized controlled trial of L-carnitine. J Child Neurol. 1999;14:162–167.
83.
TaniY, FernellE, WatanabeY, . Decrease in 6R-5,6,7,8-tetrahydrobiopterin content in cerebrospinal fluid of autistic patients. Neurosci Lett. 1994;181:169–172.
84.
KomoriH, MatsuishiT, YamadaS, . Cerebrospinal fluid biopterin and biogenic amine metabolites during oral R-THBP therapy for infantile autism. J Autism Dev Disord. 1995;25:183–193.
85.
NagahataM, KazamaturiH, NuruseH, . Clinical evaluation of apropterin hydrochloride (R-THBP) on infantile autism: a multicenter cooperative study. In: NaruseH, OrnitzEM, eds. Neurobiology of infantile autism. Proceedings of the International Symposium on Neurobiology of Infantile Autism; Nov 10-11, 1990; Tokyo, Japan. Amsterdam: Elsevier Science Ltd;1992: 351–354
86.
FernellE, WatanabeY, AdolfssonI, . Possible effects of tetrahydrobiopterin treatment in six children with autism—clinical and positron emission tomography data: a pilot study. Dev Med Child Neurol. 1997;39:313–318.
87.
DanforsT, von KnorringAL, HartvigP, . Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. J Clin Psychopharmacol. 2005;25:485–489.
88.
NakaneY, NaruseH, TakesadaM, . Clinical effect of R-THBP on infantile autism. In: NaruseH, OrnitzEM, eds. Neurobiology of infantile autism. Proceedings of the International Symposium on Neurobiology of Infantile Autism; Nov 10-11, 1990; Tokyo, Japan.Amsterdam: Elsevier Science Ltd; 1992: 337–350
89.
MonksG, JuracekL, WeigandD, . A case of scurvy in an autistic boy. Drugs J. Dermatol.2002;1:67–69.
90.
DugganCP, WestraSJ, RosenbergAE.Case records of the Massachusetts General Hospital. Case 23-2007. A 9-year-old boy with bone pain, rash, and gingival hypertrophy. N Engl J Med.2007;357:392–400.
91.
DolskeMC, SpollenJ, McKayS, . A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry. 1993;17:765–774.
92.
ChezMG, BuchananCP, AimonovitchMC, . Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol. 2002;17:833–837.
93.
AdamsJB, HollowayC.Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. Altern J. Complement Med.2004;10:1033–1039.
94.
PaczynskiM.Piracetam: a novel therapy for autism?J Autism Dev Disord.1997;27:628–630.
95.
AkhondzadehS, TajdarH, MohammadiMR, . A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry Hum Dev. 2008;39:237–245.
96.
RichardsonAJ, CalvinCM, ClisbyC, . Fatty acid deficiency signs predict the severity of reading and related difficulties in dyslexic children. Prostaglandins Leukot Essent Fatty Acids. 2000;63:69–74.
97.
RichardsonAJ.Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry. 2006;18:155–172.
98.
RichardsonAJ.Long-chain polyunsaturated fatty acids in childhood developmental and psychiatric disorders. Lipids. 2004;39:1215–1222.
99.
StevensLJ, ZentallSS, AbateML, . Omega-3 fatty acids in boys with behavior, learning, and health problems. Physiol Behav. 1996;59:915–920.
BellJG, MacKinlayEE, DickJR, . Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins Leukot Essent Fatty Acids. 2004;71:201–204.
102.
SliwinskiS, CroonenberghsJ, ChristopheA, . Polyunsaturated fatty acids: do they have a role in the pathophysiology of autism?Neuro Endocrinol Lett.2006;27:465–471.
103.
SchultzST, Klonoff-CohenHS, WingardDL, . Breastfeeding, infant formula supplementation, and autistic disorder: the results of a parent survey. Int Breastfeed J.2006;1:16.
104.
JohnsonSM, HollanderE.Evidence that eicosapentaenoic acid is effective in treating autism. J Clin Psychiatry. 2003;64:848–849.
105.
PatrickL, SalikR.The effect of essential fatty acid supplementation on language development and learning skills in autism and Asperger's syndrome. Autism Asperger's Digest.2005;Jan/Feb:36–37.
106.
PolitiP, CenaH, ComelliM, . Behavioral effects of omega-3 fatty acid supplementation in young adults with severe autism: an open label study. Arch Med Res. 2008;39:682–685.
107.
MeguidNA, AttaHM, GoudaAS, . Role of polyunsaturated fatty acids in the management of Egyptian children with autism. Clin Biochem. 2008;41:1044–1048.
108.
AmmingerGP, BergerGE, SchaferMR, . Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry. 2007;61:551–553.
109.
BentS, BertoglioK, HendrenRL.Omega-3 fatty acids for autistic spectrum disorder: a systematic review. J Autism Dev Disord. 2009; 39:1145–1154.
110.
AdamsJB, GeorgeF, AudhyaT.Abnormally high plasma levels of vitamin B6 in children with autism not taking supplements compared to controls not taking supplements. Altern J. Complement Med.2006;12:59–63.
LelordG, CallawayE, MuhJP, . [Modifications in urinary homovanillic acid after ingestion of vitamin B6; functional study in autistic children (author's transl)] [In French]. Rev Neurol (Paris). 1978;134:797–801.
116.
MartineauJ, GarreauB, BarthelemyC, . Effects of vitamin B6 on averaged evoked potentials in infantile autism. Biol Psychiatry. 1981;16:627–641.
117.
MartineauJ, BarthelemyC, CheliakineC, . Brief report: an open middle-term study of combined vitamin B6-magnesium in a subgroup of autistic children selected on their sensitivity to this treatment. J Autism Dev Disord. 1988;18:435–447.
118.
MartineauJ, BarthelemyC, RouxS, . Electrophysiological effects of fenfluramine or combined vitamin B6 and magnesium on children with autistic behaviour. Dev Med Child Neurol. 1989;31:721–727.
119.
MenageP, ThibaultG, BarthelemyC, . CD 4+ CD 45 RA+ T lymphocyte deficiency in autistic children: effect of a pyridoxine-magnesium treatment. Brain Dysfunct. 1992;5:326–333.
120.
BarthelemyC, GarreauB, LeddetI, . [Biological and clinical effects of oral magnesium and associated magnesium-vitamin B6 administration on certain disorders observed in infantile autism (author's transl)] [In French]. Therapie. 1980;35:627–632.
121.
BarthelemyC, GarreauB, LeddetI.Behavioral and biological effects of oral magnesium, vitamin B6 and combined magnesium-vitamin B6 administration in autistic children. Magnes Bull. 1981;2:150–153.
122.
JonasC, EtienneT, BarthelemyC, . [Clinical and biochemical value of Magnesium + vitamin B6 combination in the treatment of residual autism in adults] [In French]. Therapie. 1984;39:661–669.
123.
MartineauJ, BarthelemyC, GarreauB, . Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism. Biol Psychiatry. 1985;20:467–478.
124.
LelordG, MuhJP, BarthelemyC, . Effects of pyridoxine and magnesium on autistic symptoms—initial observations. J Autism Dev Disord. 1981;11:219–230.
125.
LelordG, CallawayE, MuhJP.Clinical and biological effects of high doses of vitamin B6 and magnesium on autistic children. Acta Vitaminol Enzymol. 1982;4:27–44.
126.
RimlandB, CallawayE, DreyfusP.The effect of high doses of vitamin B6 on autistic children: a double-blind crossover study. Am Psychiatry J.1978;135:472–475.
127.
TolbertL, HaiglerT, WaitsMM, . Brief report: lack of response in an autistic population to a low dose clinical trial of pyridoxine plus magnesium. J Autism Dev Disord. 1993;23:193–199.
128.
FindlingRL, MaxwellK, Scotese-WojtilaL, . High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study. J Autism Dev Disord. 1997;27:467–478.
129.
KuriyamaS, KamiyamaM, WatanabeM, . Pyridoxine treatment in a subgroup of children with pervasive developmental disorders. Dev Med Child Neurol. 2002;44:284–286.
Mousain-BoscM, RocheM, PolgeA, . Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism. Magnes Res.2006;19:53–62.
132.
McGuireJK, KulkarniMS, BadenHP.Fatal hypermagnesemia in a child treated with megavitamin/megamineral therapy. Pediatrics.2000;105:E18.
133.
WakefieldAJ, MurchSH, AnthonyA, . Ileallymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351:637–641.
134.
LoweTL, CohenDJ, MillerS, . Folic acid and B12 in autism and neuropsychiatric disturbances of childhood. J Am Acad Child Psychiatry. 1981;20:104–111.
135.
GillbergC, WahlstromJ, JohanssonR, . Folic acid as an adjunct in the treatment of children with the autism fragile-X syndrome (AFRAX). Dev Med Child Neurol. 1986;28:624–627.
136.
NakanoK, NodaN, TachikawaE, . A preliminary study of methylcobalamin therapy in autism. Journal of Tokyo Women's Medical University. 2005;75:64–69.
137.
JamesSJ, MelnykS, FuchsG, . Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism. Am J Clin Nutr. 2009;89:1–6.
138.
MorettiP, PetersSU, Del GaudioD, . Brief report: autistic symptoms, developmental regression, mental retardation, epilepsy, and dyskinesias in CNS folate deficiency. J Autism Dev Disord. 2008;38:1170–1177.
139.
MorettiP, SahooT, HylandK, . Cerebral folate deficiency with developmental delay, autism, and response to folinic acid. Neurology. 2005;64:1088–1090.
140.
RamaekersVT, BlauN, SequeiraJM, . Folate receptor autoimmunity and cerebral folate deficiency in low-functioning autism with neurological deficits. Neuropediatrics. 2007;38:276–281.
141.
RamaekersVT, SequeiraJM, BlauN, . A milk-free diet downregulates folate receptor autoimmunity in cerebral folate deficiency syndrome. Dev Med Child Neurol. 2008;50:346–352.
142.
NiederhoferH.First preliminary results of an observation of Ginkgo Biloba treating patients with autistic disorder. Phytother Res. 2009 Mar 9. [E-pub ahead of print.] 143.
143.
LevineJ, AviramA, HolanA, . Inositol treatment of autism. Neural J. Transm.1997;104:307–310.
144.
LozoffB, BeardJ, ConnorJ, . Long-lasting neural and behavioral effects of iron deficiency in infancy. Nutr Rev.2006;64:S34–43; discussion S72-91.
145.
HaltermanJS, KaczorowskiJM, AligneCA, . Iron deficiency and cognitive achievement among schoolaged children and adolescents in the United States. Pediatrics. 2001;107:1381–1386.
146.
BrunerAB, JoffeA, DugganAK, . Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet. 1996;348:992–996.
147.
LatifA, HeinzP, CookR.Iron deficiency in autism and Asperger syndrome. Autism. 2002;6:103–114.
148.
DosmanCF, DrmicIE, BrianJA, . Ferritin as an indicator of suspected iron deficiency in children with autism spectrum disorder: prevalence of low serum ferritin concentration. Dev Med Child Neurol. 2006;48:1008–1009.
149.
CornishE.A balanced approach towards healthy eating in autism. Journal of Human Nutrition and Dietetics. 1998;11:501–509.
150.
DosmanCF, BrianJA, DrmicIE, . Children with autism: effect of iron supplementation on sleep and ferritin. Pediatr Neurol. 2007;36:152–158.
151.
SandlerRH, FinegoldSM, BolteER, . Short-term benefit from oral vancomycin treatment of regressiveonset autism. J Child Neurol. 2000;15:429–435.
152.
BrudnakMA, RimlandB, KerryRE, . Enzymebased therapy for autism spectrum disorders—is it worth another look?Med Hypotheses.2002;58:422–428.
153.
BrudnakMA.Probiotics as an adjuvant to detoxification protocols. Med Hypotheses. 2002;58:382–385.
154.
BladesM.Autism: an interesting dietary case history. Nutrition and Food Science. 2000;30:137–140.
155.
NiederhoferH.St John's Wort treating patients with autistic disorder. Phytother Res. 2009;Mar 9[Epub ahead of print].
156.
BolmanWM, RichmondJA.A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. J Autism Dev Disord. 1999;29:191–194.
157.
KernJK, MillerVS, CaullerPL, . Effectiveness of N, N-dimethylglycine in autism and pervasive developmental disorder. J Child Neurol. 2001;16:169–173.
158.
McDougleCJ, NaylorST, CohenDJ, . Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry. 1996;53:993–1000.
159.
SverdJ, KupietzSS, WinsbergBG, . Effects of L-5-hydroxytryptophan in autistic children. J Autism Child Schizophr. 1978;8:171–180.
160.
CannellJJ.Autism and vitamin D. Med Hypotheses. 2008;70:750–759.
161.
StewartC, LatifA.Symptomatic nutritional rickets in a teenager with autistic spectrum disorder. Child Care Health Dev. 2008;34:276–278.
162.
ClarkJH, RhodenDK, TurnerDS.Symptomatic vitamin A and D deficiencies in an eight-year-old with autism. JPEN Parenter J. Enteral Nutr.1993;17:284–286.
163.
SteinemannTL, ChristiansenSP.VitaminAdeficiency and xerophthalmia in an autistic child. Arch Ophthalmol. 1998;116:392–393.
164.
UyanikO, DogangunB, KayaalpL, . Food faddism causing vision loss in an autistic child. Child Care Health Dev. 2006;32:601–602.
165.
MegsonMN.Is autism a G-alpha protein defect reversible with natural vitamin A? Med Hypotheses. 2000;54:979–983.
166.
ShaywitzBA, SiegelNJ, PearsonHA.Megavitamins for minimal brain dysfunction. A potentially dangerous therapy. JAMA. 1977;238:1749–1750.
167.
KimmounA, LeheupB, FeilletF, . [Hypercalcemia revealing iatrogenic hypervitaminosis A in a child with autistic troubles] [In French]. Arch Pediatr. 2008;15:29–32.
168.
JoryJ, McGinnisWR.Red-cell trace minerals in children with autism. Am Biochem J. Biotech.2008;4:101–104.
169.
PfeifferCC, Braverman ZincER., The brain and behavior. Biol Psychiatry.1982;17:513–532.
170.
YorbikO, OlgunA, KirmizigulP, . [Plasma zinc and copper levels in boys with oppositional defiant disorder] [In Turkish]. Turk Psikiyatri Derg. 2004;15:276–281.
171.
JacksonMJ, GarrodPJ.Plasma zinc, copper, and amino acid levels in the blood of autistic children. J Autism Child Schizophr. 1978;8:203–208.
172.
YorbikO, AkayC, SayalA, . Zinc status in autistic children. Trace J. Elem Exp Med.2004;17:101–107.
173.
PankseppJ.A neurochemical theory of autism. Trends Neurosci. 1979;2:174–177.
174.
VojdaniA, CampbellAW, AnyanwuE, . Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. Neuroimmunol J.2002;129:168–177.
175.
VojdaniA, PangbornJB, VojdaniE, . Infections, toxic chemicals and dietary peptides binding to lymphocyte receptors and tissue enzymes are major instigators of autoimmunity in autism. Int Immunopathol J. Pharmacol.2003;16:189–199.
176.
VojdaniA, O'BryanT, GreenJA, . Immune response to dietary proteins, gliadin and cerebellar peptides in children with autism. Nutr Neurosci. 2004;7:151–161.
177.
VojdaniA, BazarganM, VojdaniE, . Heat shock protein and gliadin peptide promote development of peptidase antibodies in children with autism and patients with autoimmune disease. Clin Diagn Lab Immunol. 2004;11:515–524.
178.
JyonouchiH, SunS, ItokazuN.Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology. 2002;46:76–84.
179.
AshwoodP, AnthonyA, TorrenteF, . Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory interleukin-10. J Clin Immunol. 2004;24:664–673.
180.
AfzalN, MurchS, ThirrupathyK, . Constipation with acquired megarectum in children with autism. Pediatrics. 2003;112:939–942.
181.
BarciaG, PosarA, SantucciM, . Autism and coeliac disease. J Autism Dev Disord. 2008;38:407–408.
EvangeliouA, VlachonikolisI, MihailidouH, . Application of a ketogenic diet in children with autistic behavior: pilot study. J Child Neurol. 2003;18:113–118.
SponheimE.[Gluten-free diet in infantile autism. A therapeutic trial] [In Norwegian]. Tidsskr Nor Laegeforen.1991;111:704–707.
186.
ReicheltKL, EkremJ, Scott GlutenH., milk proteins and autism: dietary intervention effects on behavior and peptide secretion. J Appl Nutr.1990;42:1–11.
KnivsbergAM, ReicheltKL, NodlandM, . Autistic symptoms and diet: a follow-up study. Scand Ed J. Research.1995;39:223–236.
189.
WhiteleyP, RodgersJ, SaveryD, . A gluten-free diet as an intervention for autism and associated spectrum disorders: preliminary findings. Autism. 1999;3:45.
ChristisonGW, IvanyK.Elimination diets in autism spectrum disorders: any wheat amidst the chaff?J Dev Behav Pediatr.2006;27:S162–S171.
192.
Goin-KochelRP, MackintoshVH, MyersBJ.Parental reports on the efficacy of treatments and therapies for their children with autism spectrum disorders. Research in Autism Spectrum Disorders. 2009;3:528–537.
193.
KnivsbergAM, ReicheltKL, HoienT, . A randomised, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci. 2002;5:251–261.
194.
ElderJH, ShankarM, ShusterJ, . The gluten-free, casein-free diet in autism: results of a preliminary double blind clinical trial. J Autism Dev Disord. 2006;36:413–420.
AdamsSJ, BurtonN, CutressA, . Development of double blind gluten and casein free test foods for use in an autism dietary trial. Hum J. Nutr Diet.2008;21:374.
197.
ArnoldGL, HymanSL, MooneyRA, . Plasma amino acids profiles in children with autism: potential risk of nutritional deficiencies. J Autism Dev Disord. 2003;33:449–454.
198.
HedigerML, EnglandLJ, MolloyCA, . Reduced bone cortical thickness in boys with autism or autism spectrum disorder. J Autism Dev Disord. 2008;38:848–856.
199.
PerryEK, LeeML, Martin-RuizCM, . Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am Psychiatry J.2001;158:1058–1066.
200.
ChezMG, AimonovitchM, BuchananT, . Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol. 2004;19:165–169.
201.
HardanAY, HandenBL.A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 2002;12:237–241.
202.
ChezMG, NowinskiCV, BuchananCP.Donepezil use in children with autistic spectrum disorders. Ann Neurol. 2000;48:541.
203.
ChezMG, BuchananTM, BeckerM, . Donepezil hydrochloride: a double-blind study in autistic children. J Pediatr Neurol. 2003;1:83–88.
204.
HertzmanM.Galantamine in the treatment of adult autism: a report of three clinical cases. Int Psychiatry J. Med.2003;33:395–398.
205.
NicolsonR, Craven-ThussB, SmithJ.A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol. 2006;16:621–629.
206.
NiederhoferH, StaffenW, MairA.Galantamine may be effective in treating autistic disorder. BMJ. 2002;325:1422.
207.
CampbellM, AndersonLT, SmallAM, . Naltrexone in autistic children: a double-blind and placebo-controlled study. Psychopharmacol Bull. 1990;26:130–135.
208.
LeboyerM, BouvardMP, LaunayJM, . Brief report: a double-blind study of naltrexone in infantile autism. J Autism Dev Disord. 1992;22:309–319.
209.
Willemsen-SwinkelsSH, BuitelaarJK, WeijnenFG, . Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res. 1995;58:203–215.
210.
BouvardMP, LeboyerM, LaunayJM, . Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Res. 1995;58:191–201.
211.
KolmenBK, FeldmanHM, HandenBL, . Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study. J Am Acad Child Adolesc Psychiatry. 1995;34:223–231.
212.
Willemsen-SwinkelsSH, BuitelaarJK, Van EngelandH.The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry. 1996;39:1023–1031.
213.
ElchaarGM, MaischNM, AugustoLM, . Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Ann Pharmacother. 2006;40:1086–1095.
214.
KoshesRJ, RockNL.Use of clonidine for behavioral control in an adult patient with autism. Am Psychiatry J.1994;151:1714.
215.
MingX, GordonE, KangN, . Use of clonidine in children with autism spectrum disorders. Brain Dev. 2008;30:454–460.
216.
FankhauserMP, KarumanchiVC, GermanML, . A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry. 1992;53:77–82.
217.
JaselskisCA, CookEHJr, FletcherKE, . Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol. 1992;12:322–327.
218.
PoseyDJ, PuntneyJI, SasherTM, . Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol. 2004;14:233–241.
219.
ScahillL, AmanMG, McDougleCJ, . A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16:589–598.
220.
HandenBL, SahlR, HardanAY.Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr. 2008;29:303–308.
221.
BoellnerSW, PennickM, FiskeK, . Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy. 2007;27:1253–1262.
222.
RossignolDA.Hyperbaric oxygen therapy might improve certain pathophysiological findings in autism. Med Hypotheses. 2007;68:1208–1227.
223.
RossignolDA, RossignolLW.Hyperbaric oxygen therapy may improve symptoms in autistic children. Med Hypotheses. 2006;67:216–228.
224.
RossignolDA, RossignolLW, JamesSJ, . The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study. BMC Pediatr. 2007;7:36.
225.
ChungpaibulpatanaJ, SumpatanaraxT, ThadakulN, . Hyperbaric oxygen therapy in Thai autistic children. J Med Assoc Thai. 2008;91:1232–1238.
226.
RossignolDA, RossignolLW, SmithS, . Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. BMC Pediatr. 2009;9:21.
227.
ShenoyS, ArnoldS, ChatilaT.Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome. J Pediatr. 2000;136:682–687.
228.
StefanatosGA, GroverW, GellerE.Case study: corticosteroid treatment of language regression in pervasive developmental disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:1107–1111.
229.
ChezMG, LoeffelM, BuchananC, . Pulse high dose steroids as combination therapy with valproic acid in epileptic aphasia patients with pervasive developmental delay or autism. Ann Neurol. 1998;44:539.
230.
BuitelaarJK, Van EngelandH, de KogelK, . The adrenocorticotrophic hormone (4-9) analog ORG 2766 benefits autistic children: report on a second controlled clinical trial. J Am Acad Child Adolesc Psychiatry. 1992;31:1149–1156.
231.
BuitelaarJK, Van EngelandH, de KogelKH, . The use of adrenocorticotrophic hormone (4-9) analog ORG 2766 in autistic children: effects on the organization of behavior. Biol Psychiatry. 1992;31:1119–1129.
232.
BuitelaarJK, Van EngelandH, Van ReeJM, . Behavioral effects of Org 2766, a synthetic analog of the adrenocorticotrophic hormone (4-9), in 14 outpatient autistic children. J Autism Dev Disord. 1990;20:467–478.
233.
BorisM, KaiserCC, GoldblattA, . Effect of pioglitazone treatment on behavioral symptoms in autistic children. Neuroinflammation J.2007;4:3.
234.
BradstreetJJ, SmithS, GranpeeshehD, . Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders. Med Hypotheses. 2007;68:979–987.
235.
GuptaS, RimlandB, ShillingPD.Pentoxifylline: brief review and rationale for its possible use in the treatment of autism. J Child Neurol. 1996;11:501–504.
236.
HeuerL, AshwoodP, SchauerJ, . Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms. Autism Res. 2008;1:275–283.
237.
GuptaS, AggarwalS, HeadsC.Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord. 1996;26:439–452.
238.
PlioplysAV.Intravenous immunoglobulin treatment of children with autism. J Child Neurol. 1998;13:79–82.
239.
GuptaS.Immunological treatments for autism. J Autism Dev Disord. 2000;30:475–479.
240.
DelGiudice-AschG, SimonL, SchmeidlerJ, . Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disord. 1999;29:157–160.
241.
PlioplysAV.Intravenous immunoglobulin treatment in autism. J Autism Dev Disord. 2000;30:73–74.
242.
BorisM, GoldblattA, EdelsonSM.Improvement in children with autism treated with intravenous gamma globulin. Nutritional J. Environmental Medicine.2005;15:169–176.
243.
SchneiderCK, MelmedRD, BarstowLE, . Oral human immunoglobulin for children with autism and gastrointestinal dysfunction: a prospective, open-label study. J Autism Dev Disord. 2006;36:1053–1064.
244.
HandenBL, MelmedRD, HansenRL, . A doubleblind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder. J Autism Dev Disord. 2009;39:796–805.
245.
StubbsEG, BuddenSS, BurgerDR, . Transfer factor immunotherapy of an autistic child with congenital cytomegalovirus. J Autism Dev Disord. 1980;10:451–458.
246.
FudenbergHH.Dialysable lymphocyte extract (DLyE) in infantile onset autism: a pilot study. Biotherapy. 1996;9:143–147.
247.
BartzJA, HollanderE.Oxytocin and experimental therapeutics in autism spectrum disorders. Prog Brain Res. 2008;170:451–462.
248.
LererE, LeviS, SalomonS, . Association between the oxytocin receptor (OXTR) gene and autism: relationship to Vineland Adaptive Behavior Scales and cognition. Mol Psychiatry. 2008;13:980–988.
249.
WuS, JiaM, RuanY, . Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han population. Biol Psychiatry. 2005;58:74–77.
250.
JacobS, BruneCW, CarterCS, . Association of the oxytocin receptor gene (OXTR) in Caucasian children and adolescents with autism. Neurosci Lett. 2007;417:6–9.
HollanderE, NovotnyS, HanrattyM, . Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology. 2003;28:193–198.
254.
HollanderE, BartzJ, ChaplinW, . Oxytocin increases retention of social cognition in autism. Biol Psychiatry. 2007;61:498–503.
255.
CohenDJ, JohnsonWT, CaparuloBK.Pica and elevated blood lead level in autistic and atypical children. Am Dis J. Child.1976;130:47–48.
256.
AccardoP, WhitmanB, CaulJ, . Autism and plumbism. A possible association. Clin Pediatr (Phila). 1988;27:41–44.
257.
EpprightTD, SanfaconJA, HorwitzEA.Attention deficit hyperactivity disorder, infantile autism, and elevated blood-lead: a possible relationship. Mo Med. 1996;93:136–138.
258.
LidskyTI, SchneiderJS.Autism and autistic symptoms associated with childhood lead poisoning. Journal of Applied Research. 2005;5:80–87.
259.
KiddPM.Autism, an extreme challenge to integrative medicine. Part II: medical management. Alternative Medicine Review.2002;7:472–499.
260.
LonsdaleD, ShambergerRJ, AudhyaT.Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study. Neuro Endocrinol Lett. 2002;23:303–308.
261.
GeierDA, GeierMR.A clinical trial of combined anti-androgen and anti-heavy metal therapy in autistic disorders. Neuro Endocrinol Lett. 2006;27:833–838.
262.
PatelK, CurtisLT.A comprehensive approach to treating autism and attention-deficit hyperactivity disorder: a prepilot study. Altern J. Complement Med.2007;13:1091–1097.
263.
NatafR, SkorupkaC, AmetL, . Porphyrinuria in childhood autistic disorder: implications for environmental toxicity. Toxicol Appl Pharmacol. 2006;214:99–108.
264.
BradstreetJJ, GeierDA, KartzinelJJ, . A casecontrol study of mercury burden in children with autistic spectrum disorders. Journal of American Physicians and Surgeons. 2003;8:76–79.
265.
SodenSE, LowryJA, GarrisonCB, . 24-hour provoked urine excretion test for heavy metals in children with autism and typically developing controls, a pilot study. Clin Toxicol (Phila). 2007;45:476–481.
266.
ShannonM, GraefJW.Lead intoxication in children with pervasive developmental disorders. Toxicol J. Clin Toxicol.1996;34:177–181.
267.
GeierDA, GeierMR.A prospective assessment of porphyrins in autistic disorders: a potential marker for heavy metal exposure. Neurotox Res. 2006;10:57–64.
268.
GeierDA, GeierMR.A prospective study of mercury toxicity biomarkers in autistic spectrum disorders. Toxicol J. Environ Health A.2007;70:1723–1730.
269.
van der LindeAA, PillenS, GerritsGP, . Stevens-Johnson syndrome in a child with chronic mercury exposure and 2,3-dimercaptopropane-1-sulfonate (DMPS) therapy. Clin Toxicol (Phila). 2008;46:479–481.
270.
BrownMJ, WillisT, OmaluB, . Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005. Pediatrics. 2006;118: e534–536.
271.
ChenZK, LuZQ.Sodium dimercaptopropane sulfonate as antidote against non-metallic pesticides. Acta Pharmacol Sin. 2004;25:534–544.
272.
FloraSJ, PandeM, MehtaA.Beneficial effect of combined administration of some naturally occurring antioxidants (vitamins) and thiol chelators in the treatment of chronic lead intoxication. Chem Biol Interact. 2003;145:267–280.
273.
FloraSJ, FloraG, SaxenaG, . Arsenic and lead induced free radical generation and their reversibility following chelation. Cell Mol Biol (Noisy-le-grand). 2007;53:26–47.
274.
RoganWJ, DietrichKN, WareJH, . The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med. 2001;344:1421–1426.
275.
DietrichKN, WareJH, SalganikM, . Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. Pediatrics. 2004;114:19–26.
276.
BhattacharyaA, ShuklaR, AuyangED, . Effect of succimer chelation therapy on postural balance and gait outcomes in children with early exposure to environmental lead. Neurotoxicology. 2007;28:686–695.
GudarziSS, YasamyM, AkhondzadehS.Cyproheptadine in treatment of autism. Eur Psychiatry. 2002;17:230–231.
279.
AkhondzadehS, ErfaniS, MohammadiMR, . Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. J Clin Pharm Ther. 2004;29:145–150.
280.
LindayLA.Oral famotidine: a potential treatment for children with autism. Med Hypotheses. 1997;48:381–386.
281.
LindayLA, TsiourisJA, CohenIL, . Famotidine treatment of children with autistic spectrum disorders: pilot research using single subject research design. Neural J. Transm.2001;108:593–611.
282.
PurcellAE, JeonOH, ZimmermanAW, . Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology. 2001;57:1618–1628.
EricksonCA, ChambersJE.Memantine for disruptive behavior in autistic disorder. J Clin Psychiatry. 2006;67:1000.
285.
EricksonCA, PoseyDJ, StiglerKA, . A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl). 2007;191:141–147.
286.
OwleyT, SaltJ, GuterS, . A prospective, openlabel trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16:517–524.
287.
ChezMG, BurtonQ, DowlingT, . Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007;22:574–579.
288.
UldallP, HansenFJ, TonnbyB.Lamotrigine in Rett syndrome. Neuropediatrics. 1993;24:339–340.
289.
MendhekarDN, DuggalHS.Acquired variant of Rett's disorder and response to lamotrigine. Neuropsychiatry J. Clin Neurosci.2007;19:474–475.
290.
KumandasS, CaksenH, CiftciA, . Lamotrigine in two cases of Rett syndrome. Brain Dev. 2001;23:240–242.
291.
StenbomY, TonnbyB, HagbergB.Lamotrigine in Rett syndrome: treatment experience from a pilot study. Eur Child Adolesc Psychiatry. 1998;7:49–52.
292.
UvebrantP, BauzieneR.Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics.1994;25:284–289.
293.
BelsitoKM, LawPA, KirkKS, . Lamotrigine therapy for autistic disorder: a randomized, doubleblind, placebo-controlled trial. J Autism Dev Disord. 2001;31:175–181.
294.
PoseyDJ, KemDL, SwiezyNB, . A pilot study of D-cycloserine in subjects with autistic disorder. Am Psychiatry J.2004;161:2115–2117.
295.
SturmeyP.Secretin is an ineffective treatment for pervasive developmental disabilities: a review of 15 double-blind randomized controlled trials. Res Dev Disabil. 2005;26:87–97.
296.
EschBE, CarrJE.Secretin as a treatment for autism: a review of the evidence. J Autism Dev Disord. 2004;34:543–556.
Ratliff-SchaubK, CareyT, ReevesGD, . Randomized controlled trial of transdermal secretin on behavior of children with autism. Autism. 2005;9:256–265.
299.
BosoM, EmanueleE, MinazziV, . Effect of longterm interactive music therapy on behavior profile and musical skills in young adults with severe autism. Altern J. Complement Med.2007;13:709–712.
300.
KernP, AldridgeD.Using embedded music therapy interventions to support outdoor play of young children with autism in an inclusive community-based child care program. Music J. Ther.2006;43:270–294.
301.
KimJ, WigramT, GoldC.The effects of improvisational music therapy on joint attention behaviors in autistic children: a randomized controlled study. J Autism Dev Disord. 2008;38:1758–1766.
302.
CorbettBA, ShickmanK, FerrerE.Brief report: the effects of Tomatis sound therapy on language in children with autism. J Autism Dev Disord. 2008;38:562–566.
303.
WhippleJ.Music in intervention for children and adolescents with autism: a meta-analysis. Music J. Ther.2004;41:90–106.
KaplanM, CarmodyDP, GaydosA.Postural orientation modifications in autism in response to ambient lenses. Child Psychiatry Hum Dev. 1996;27:81–91.
306.
KaplanM, EdelsonSM, SeipJA.Behavioral changes in autistic individuals as a result of wearing ambient transitional prism lenses. Child Psychiatry Hum Dev. 1998;29:65–76.
307.
ChenWX, Wu-LiL, WongVC.Electroacupuncture for children with autism spectrum disorder: pilot study of 2 cases. Altern J. Complement Med.2008;14:1057–1065.
308.
AllamH, El DineNG, HelmyG.Scalp acupuncture effect on language development in children with autism: a pilot study. Altern J. Complement Med.2008;14:109–114.
309.
RimlandB, EdelsonSM.Brief report: a pilot study of auditory integration training in autism. J Autism Dev Disord. 1995;25:61–70.
310.
SinhaY, SiloveN, WheelerD, . Auditory integration training and other sound therapies for autism spectrum disorders: a systematic review. Arch Dis Child. 2006;91:1018–1022.
311.
Cullen-PowellLA, BarlowJH, CushwayD.Exploring a massage intervention for parents and their children with autism: the implications for bonding and attachment. J Child Health Care. 2005;9:245–255.
312.
WilliamsTI.Evaluating effects of aromatherapy massage on sleep in children with autism: a pilot study. Evid Based Complement Alternat Med. 2006;3:373–377.
313.
EscalonaA, FieldT, Singer-StrunckR, . Brief report: improvements in the behavior of children with autism following massage therapy. J Autism Dev Disord. 2001;31:513–516.
314.
SilvaLM, CignoliniA.A medical qigong methodology for early intervention in autism spectrum disorder: a case series. Am Chin J. Med.2005;33:315–327.
315.
SilvaLM, AyresR, SchalockM.Outcomes of a pilot training program in a qigong massage intervention for young children with autism. Am Occup J. Ther.2008;62:538–546.
316.
SilvaLM, CignoliniA, WarrenR, . Improvement in sensory impairment and social interaction in young children with autism following treatment with an original Qigong massage methodology. Am Chin J. Med.2007;35:393–406.
317.
JarusiewiczB.Efficacy of neurofeedback for children in the autism spectrum: a pilot study. Neurotherapy J.2002;6:39–49.
318.
RobinsonTW.Homeopathic secretin in autism: a clinical pilot study. British Homeopathic Journal. 2001;90:86–91.
319.
WarwickTC, GriffithJ, ReyesB, . Effects of vagus nerve stimulation in a patient with temporal lobe epilepsy and Asperger syndrome: case report and review of the literature. Epilepsy Behav. 2007;10:344–347.
320.
ParkYD.The effects of vagus nerve stimulation therapy on patients with intractable seizures and either Landau-Kleffner syndrome or autism. Epilepsy Behav. 2003;4:286–290.
321.
DanielssonS, ViggedalG, GillbergC, . Lack of effects of vagus nerve stimulation on drug-resistant epilepsy in eight pediatric patients with autism spectrum disorders: a prospective 2-year follow-up study. Epilepsy Behav. 2008;12:298–304.
